Free tool
FAERS Monitor: Iressa
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 206995 or its brand name (Iressa, Gefitinib). Reports on generic versions are filed under their own applications.
Reports
8,993
Serious
8,525
95% of reports
Hospitalization
2,580
Death reported
1,955
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- malignant neoplasm progression1,824
- drug resistance1,253
- diarrhoea907
- death758
- rash643
- disease progression462
- interstitial lung disease420
- nausea380
- metastases to central nervous system377
- dyspnoea332
- vomiting326
- drug ineffective299
- pneumonia271
- pyrexia270
- acquired gene mutation259
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 801 |
| 2005 | 515 |
| 2006 | 1,182 |
| 2007 | 235 |
| 2008 | 214 |
| 2009 | 194 |
| 2010 | 240 |
| 2011 | 333 |
| 2012 | 87 |
| 2013 | 37 |
| 2014 | 48 |
| 2015 | 239 |
| 2016 | 503 |
| 2017 | 557 |
| 2018 | 614 |
| 2019 | 990 |
| 2020 | 713 |
| 2021 | 430 |
| 2022 | 278 |
| 2023 | 283 |
| 2024 | 249 |
| 2025 | 181 |
| 2026 | 70 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,045,166 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| acquired gene mutationSignal | 259 | 576.1 | 503.7 | 118,872 |
| drug resistanceSignal | 1,253 | 119.9 | 113.7 | 140,573 |
| metastases to central nervous systemSignal | 377 | 70.4 | 63.7 | 24,983 |
| malignant neoplasm progressionSignal | 1,824 | 42.4 | 40.7 | 72,721 |
| interstitial lung diseaseSignal | 420 | 20.5 | 18.6 | 7,703 |
| disease progressionSignal | 462 | 9.2 | 8.4 | 3,358 |
| rashSignal | 643 | 3.5 | 3.2 | 1,140 |
| diarrhoeaSignal | 907 | 3.3 | 3.1 | 1,487 |
| deathSignal | 758 | 2.1 | 1.9 | 429 |
| pneumonia | 271 | 2.0 | 1.7 | 128 |
| pyrexia | 270 | 1.8 | 1.6 | 102 |
| vomiting | 326 | 1.6 | 1.5 | 79 |
| dyspnoea | 332 | 1.4 | 1.2 | 34 |
| nausea | 380 | 1.1 | 1.0 | 5 |
| drug ineffective | 299 | 0.5 | 0.5 | 132 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.